“BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis As Assessed by the Static Physician’s Global Assessment (sPGA) Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI”. SKIN The Journal of Cutaneous Medicine 4, no. 5 (September 2, 2020): s29. Accessed May 18, 2025. https://skin.dermsquared.com/skin/article/view/978.